tldrdaily.news logo

Intellia Withdraws from Hemophilia Collaboration with Regeneron

1 min read
Source: Endpoints News
Intellia Withdraws from Hemophilia Collaboration with Regeneron
Photo: Endpoints News
TL;DR Summary

Intellia has exited a partnership with Regeneron to develop a factor IX gene editing therapy for hemophilia B, opting out of a deal that was signed in 2020. Despite this, Intellia remains eligible for up to $320 million in future milestones and still holds a 35% stake in a factor XIII insertion program for hemophilia A.

Topics:business#biotechnology#crispr#gene-editing#hemophilia-b#intellia#regeneron
Share this article
  1. Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise  Endpoints News
  2. Intellia opts out of hemophilia gene editing work with Regeneron  Fierce Biotech
  3. Intellia opts out of hemophilia pact with Regeneron (NASDAQ:NTLA)  Seeking Alpha

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

1 min

vs 1 min read

Condensed

66%

166 → 56 words

Want the full story? Read the original article

Read on Endpoints News